FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Booth Bruce				2. Issuer Name and Ticker or Trading Symbol  Kymera Therapeutics, Inc. [ KYMR ]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner			Owner			
	MERA THI	ERAPEUTICS, 1			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022								Officer below)	(give title	Othe belo	r (specify w)	
200 ARSENAL YARDS BLVD., SUITE 230					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WATER	TOWN M	IA	02472										X Form fi	led by More	Reporting Pe		
(City)	(S	tate)	(Zip)														
		Tab	le I - Non-	Deriva	tive	Sec	curities	s Ac	quired, Di	sposed c	f, or Bei	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s For ally (D) ollowing (I) (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(IIIsti. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Co	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form: Direct ( or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)					
				Co	ode \	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$14.18	06/15/2022		A	Α .		12,000		(1)	06/14/2032	Common Stock	12,000	\$0.00	12,000	D <sup>(2)</sup>		

## **Explanation of Responses:**

- 1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.
- 2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

## Remarks:

/s/ Ommer Chohan, as Attorney-in-Fact

06/16/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.